

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

إِنَّ اللَّهَ لَا يَخْفِي عَلَيْهِ شَيْءٌ فِي الْأَرْضِ وَلَا فِي السَّمَاءِ (٥) هُوَ الَّذِي
يُصَوِّرُكُمْ فِي الْأَرْضِ كَمَا يَشَاءُ لَا إِلَهَ إِلَّا هُوَ الْعَزِيزُ الْحَكِيمُ (٦)

صدق الله العظيم

سورة آل عمران الآيات ٦-٥

Dedication

This work is dedicated to my parents ..

To my brothers and sisters..

To my colleagues ..

And to all women which to have a baby...

Acknowledgement

First of all thanks is for Allah ,Praise Allah for bleesing

My work and I would like to thanks .

Dr. Mohieldeen Abaas Abdalla

I would like to thank the Department of Hematology and Immunohaematology for giving me the opportunity to conduct this important research.

Special thanks for Dr.Sara Elsadig and a person who aspire me

Dr. Tarig Mohammed Fadel elmwla

And I hope this study will come with benefit for Sudan.

Abstract

This is a descriptive analytical study carried out in Khartoum state during the period of March 20120 to June 2012 ,to evaluate hemostatic mechanism among Sudanese women with recurrent miscarriages.Fifty females with diagnosed miscarriages (three or more) were selected, and thirty healthy women were selected as control group. 4.5 ml of venous blood withdrawn from each women, placed in tri sodium citrate container, then centrifuged to get platelets poor plasma (PPP) to measure prothrombin time (PT), activated thromboplastin time (APTT), thrombin time (TT) and D-dimer. The results were analyzed by SPSS version 11.5 and express as means, The results obtained showed that the means of PT(15.8),APTT (36.1),TT(15.6) and D-dimer(787) respectively. The mean of PT,PTT, TT, and D-dimer of control group was(13.1sec), (31.4 sec), (14.5 sec), and (209 ng/ml) respectively. The results showed significant differences between the mean value of patients and controls in prothrombin time PT (P.value <0.05), activated partial thromboplastin time APTT (P.value <0.05), thrombin time TT (P.value <0.05) and D-dimer (P.value <0.05). The result show insignificant differences between age groups, trimesters of miscarriages of case. The results obtain indicated that measurement of prothrombin time(PT), activated partial thromboplastin time (APTT)and thrombin time (TT) were necessary when evaluating female with recurrent miscarriages there was clinical evidence of hemostatic abnormality.The results of this study confirmed that the D-dimer test could be use as early predictive marker for further miscarriages due to hemostatic abnormalities.

ملخص البحث

ايضا" لم تظر الدراسة فرق زو دلالة احصائية بين مجموعتي الاعمار للمرضى وفترة الاجهاض (الاولي ،الثانية). أشارت المحصلة على أن قياس زمن البروثرومبين، و زمن الثرومبوبلاستين المنشط جزئيا" و زمن الثرومبين ضرورية عند تقييم النساء المصابات باجهاض متكرر عندما لا يوجد دليل سريري يشير الي وجود خلل في عملية التجلط ، كما أظهرت النتائج ان الدي - دايمر يمكن ان يكون مفيد كعلامة توقع لحدوث اجهاض آخر ناتج من خلل في عملية التجلط.

List of Contents

No.	Contents	Page
1.	الآية	I
2.	Dedication	II
3.	Acknowledgement	III
4.	Abstract (English)	IV
5.	Abstract (Arabic)	V
6.	List of contents	VI
7.	List of Tables	XII
8.	List of Figures	XIII
9.	List of abbreviations	XIV
	Chapter One	
	Introduction and Literature review	
1.1	General introduction	1
1.2	Literature Review	3
1.2.1	Over view of hemostasis	3
1.2.1.1	Components of the primary hemostatic system	3
1.2.1.1.1	The vascular system	3
1.2.1.1.2	platelets	4
1.2.1.1.2.1	Platelet functions and kinetics	5
1.2.1.2	Coagulation	6
1.2.1.2.1	Coagulation factors	6
1.2.1.2.2	Coagulation inhibitors	11

1.2.1.2.2.1	Blood flow and hepatic degradation of clotting factors	11
1.2.1.2.2.2	Antithrombin	11
1.2.1.2.2.3	Protein C and Protein S	11
1.2.1.3	Primary hemostasis	12
1.2.1.4	Secondary hemostasis	13
1.2.1.4.1	Concepts of the coagulation cascade	14
1.2.1.4.2	Intrinsic system	1
1.2.1.4.3	Extrinsic pathway	15
1.2.1.4.4	Common pathway	15
1.2.1.5	Fibrinolysis	16
1.2.1.6	Hypercoagulability state (Thrombophilia)	18
1.2.1.6.1	Inherited hypercoagulable states	18
1.2.1.6.1.1	Antithrombin Deficiency	19
1.2.1.6.1.2	Protein C Deficiency	19
1.2.1.6.1.3	Protein S deficiency	19
1.2.1.6.1.4	Activated protein C resistance	20
1.2.1.6.1.5	Prothrombin G20210 A	20
1.2.1.6.1.6	Hyperhomocysteinemia	21
1.2.1.6.1.7	Miscellaneous	21
1.2.1.6.1.8	Screening for inherited thrombophilia	21
1.2.1.6.2	Acquired hypercoagulability	22
1.2.1.6.2.1	Lupus anticoagulant antiphospholipid antibody syndrome	22

1.2.1.6.2.2	Malignancies	24
1.2.1.6.2.3	Oral Contraceptives	24
1.2.1.7	Laboratory tests of coagulation	25
1.2.1.7.1	Prothrombin time	25
1.2.1.7.2	Partial Thromboplastin Time	26
1.2.1.7.3	Thrombin Time	27
1.2.1.7.4	D-dimer test	27
1.2.2	Recurrent miscarriage	27
1.2.2.1	definition	27
1.2.2.2	Types of pregnancy loss	27
1.2.2.2.1	Preclinical pregnancy loss	27
1.2.2.2.2	Clinical pregnancy loss	27
1.2.2.2.3	First trimester loss	28
1.2.2.2.4	Mid trimester loss	28
1.2.2.2.5	Late fetal loss	28
1.2.2.3	Causes of recurrent miscarriages	28
1.2.2.3.1	Parental chromosome abnormalities	28
1.2.2.3.2	Uterine and cervical pathology	28
1.2.2.3.3	Prothrombotic States	29
1.2.2.3.3.1	Antiphospholipid syndrome(APS),	29
1.2.2.3.3.2	Inherited Thrombophilias	29
1.2.2.3.4	Endocrinological Disorders	30
1.2.2.3.4.1	Hyper secretion of LH	30
1.2.2.3.4.2	High androgen levels	30

1.2.2.3.4.3	Hyper prolactinemia	30
1.2.2.3.4.4	Thyroid dysfunction	30
1.2.2.3.5	Diabetes mellitus	30
1.2.2.3.6	Immunological factors	31
1.2.2.3.7	Other factors	31
1.2.2.3.8	Hemostasis of normal pregnancy	31
1.2.2.3.9	Hemostatic changes associated with abnormal pregnancy	33
1.2.2.3.10	Blood coagulation proteins and platelet defects and RPL	33
1.2.3	The coagulation system in Rivanol-induced abortion	34
1.2.4	Hemostatic changes related to fibrin formation and fibrinolysis during the first trimester in normal pregnancy and in recurrent miscarriage	34
1.2.5	Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss:	35
1.2.6	Rationale	36
1.2.7	Objectives	37
1.2.7.1	General objectives	37
1.2.7.2	Specific objectives	37
	Chapter Two Materials and Methods	
2.1	Study design	38

2.2	Study approach	38
2.3	Study areas	38
2.4	Study population	38
2.5	Ethical Consideration	38
2.6	Data Collection	38
2.7	Inclusion Criteria	38
2.8	Exclusion Criteria	38
2.9	Data processing	39
2.10	Data Presentation	39
2.11	Sampling	39
2.12	Sample	39
2.13	Methods	39
2.13.1	Thrombin Time(TT)	39
2.13.1.1	Principle	39
2.13.1.2	Reagents	39
2.13.1.3	Assay procedure	39
2.13.1.4	Normal range	40
2.13.2	Prothrombin Time(PT)	40
2.13.2.1	Principle	40
2.13.2.2	Reagents	40
2.13.2.3	Assay procedure	40
2.13.2.4	Normal value	40
2.13.3	Activated Partial Thromboplastin Time (APTT)	40

2.13.3.1	Principle	41
2.13.3.2	Reagents	41
2.13.3.3	Assay procedure	41
2.13.3.4	Normal value	41
2.13.4	D-dimer test	41
2.13.4.1	Principle	41
2.13.4.2	Assay procedure	42
2.13.4.3	Normal value	42
2.14	Data analysis	42
3	Chapter Three Results	43
4	Chapter Four Discussion, conclusion and recommendations	50
4	References and appendices	
4.1	References	54
4.2	appendices	56

List of tables

No.	Names of table	Page
Table (1.1)	The coagulation factors and relative substances	09
Table (1.2)	the common causes of RM	29
Table (3.1)	Comparison of mean PT between case and control	43
Table (3.2)	Comparison of mean APTT between case and control	43
Table (3.3)	Comparison of mean TT between case and control	44
Table (3.4)	Comparison of mean D-dimer between case and control	44
Table (3.5)	The effect of trimester of miscarriages on mean of PT.	45
Table (3.6)	The effect of trimester of miscarriages on mean of APTT.	45
Table (3.7)	The effect of trimester of miscarriages on mean of TT.	46
Table (3.8)	The effect of trimester of miscarriages on mean of D-dimer.	46
Table (3.9)	The effect of age groups on PT results	47
Table (3.10)	The effect of age groups on APTT results	47
Table (3.11)	The effect of age groups on TT results	48
Table (3.12)	The effect of age groups on D-dimer results	48
Table (3.13)	The mean , medium , std.deviation ,minimum , maximum	49

List of figures

No.	Name of figure	Page
Figure 1.1	Thromboxane A2, prostacyclin pathway	14
Figure 1.2	The coagulation cascade	17
Figure 1.3	The fibrinolytic system and inhibitors	19
Figure 4.1	The means of (PT) in case and control groups	65
Figure 4.2	The means of(APTT) in case and control groups	65
Figure 4.3	The means of (TT) in case and control groups	66
Figure 4.4	The means (D-dimer) in case and control groups	66
Figure 4.5	The mean of PT (sec) in age groups of case	67
Figure 4.6	The mean of APTT (sec) in age groups of case	67
Figure 4.7	The mean of TT (sec) in age groups of case	68
Figure 4.8	The mean of D-dimer(ng/ml) in age groups of case	68
Figure 4.9	The mean of PT in different trimester	69
Figure 4.10	The mean of APTT in different trimester	69
Figure 4.11	The mean of TT in different trimester	70
Figure 4.12	The mean of D-dimer in different trimester	70

List of abbreviations

No.	Abbreviations	Words of abbreviations
1	ADP	Adenosine diphosphate
2	APAs	Antiphospholipid Antibodies
3	APTT	Activated partial thromboplastin time
4	AT	Anti thrombin
5	AT	Antithrombin
6	ATP	Adenosine triphosphate
7	CD	Cluster differentiation
8	DIC	Disseminated Itravascular coagulation.
9	EDRF	Endothelial derived relaxing factor
10	ELISA	Enzyme linked immunosorbent assay
11	F	Factor
12	FDPs	Fibrin degradation products
13	GP	Glycoprotein
14	HCG	Human chorionic gonadotropin
15	HLA	Human leukocyte antigen
16	HMWK	High molecular weight kininogen
17	INR	International normalization ratio
18	KD	Kilo Dalton
19	NO	Nitric oxide
20	PA	Plasminogen activator
21	PA1	Plasminogen activator inhibitor _1
22	PCOS	Polycystic ovary syndrome
23	PDGF	Platelets derived growth factor
24	PF3	Platelets factor 3

25	PG	Prostaglandin
26	PNP	Platelet neutralization procedure
27	PPROM	Preterm premature rupture of membrane
28	PT	Prothrombin time
29	PTL	Preterm labour
30	RM	Recurrent miscarriage
31	RPL	Recurrent pregnancy loss
32	TAT	Thrombin_anti thrombin
33	TF	Tissue factor
34	TFPI	Tissue factor pathway inhibitor
35	TM	Thrombomodulin
36	tPA	Tissue plasminogen activator
37	TT	Thrombin time
38	TXA2	Thromboxane A2
39	VDRL	Venereal disease research laboratory
40	vWF	Von willebrand factor
41	ZPI	Protein Z –related protease inhibitor